

Sheet 1 of 4

37 CFR 1.501  
INFORMATION DISCLOSURE STATEMENT  
IN A PATENT  
(use several sheets if necessary)

Docket No.  
112703-035Serial No.  
09286,818Applicant  
Ream et al.Filing Date  
April 6, 1999Group App.  
Unit  
1761300

## U.S. PATENT DOCUMENTS

Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing Date If appropriate
S.T	AA	4,154,814	May 15, 1979	Hand et al.			
	AB	4,400,372	Aug. 23, 1983	Muhler et al.			
	AC	4,474,749	Oct. 2, 1984	Kruppa			
	AD	4,563,345	Jan. 7, 1986	Arrick			
	AE	4,647,450	Mar. 3, 1987	Peters et al.			
	AF	4,755,389	July 5, 1988	Jones et al.			
	AG	4,822,597	Apr. 18, 1989	Faust et al.			
	AH	4,822,816	Apr. 18, 1989	Markham			
	AI	4,828,820	May 9, 1989	Glass et al.			
	AJ	4,832,994	May 23, 1989	Fey			
	AK	4,849,227	July 18, 1989	Cho			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		AL	84/02271	PCT WO				
		AM	90/12583	PCT WO				
		AN	92/06680	PCT WO				
		AO	2,706,771	France				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Akitoshi et al., Abstract "Acceleration of Transdermal Absorption of Pharmaceuticals by Essential Oils and Organic Solvents," Chem. Abst., 112:125228t, 1990.
	AQ	Bradford, A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding, Analytical Biochemistry, 72:248-254 (1976).
	AR	Nielsen et al., P-Glycoprotein as Multidrug Transporter: A Critical Review of Current Multidrug Resistant Cell Lines, Chimica et Biophysica Acta., 1139:169-183 (1992).
	AS	Adams, M.W., d-Alpha Tocopheryl Polyethylene glycol 1000 Succinate (Eastman vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds, 6th International Conference on Pharmaceutical Technology, Paris, 2-4 June, 1992.
S.T	AT	Chang, Tammy et al., "The Effect of Water-Soluble Bitamin E on Cyclosporine Pharmacokinetics in Healthy Volunteers," Abstract in American Society to Clinical Pharmacology and Therapeutics, 57(2):163, Feb. 1995.


Examiner

S.T

Date Considered

5/29/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 4

37 CFR 1.501  
INFORMATION DISCLOSURE STATEMENT  
IN A PATENT  
(use several sheets if necessary)

Docket No.  
112703-035

Serial No.  
09/286,818

Applicant  
Ream et al.

Filing Date  
April 6, 1999

Group Art  
Unit  
1761

U.S. PATENT DOCUMENTS

Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing Date If appropriate
S.T.	BA	4,853,212	Aug. 1, 1989	Faust et al.			
	BB	4,867,989	Sep. 19, 1989	Silva et al.			
	BC	4,908,211	Mar. 13, 1990	Paz			
	BD	4,908,212	Mar. 13, 1990	Kwon et al.			
	BE	4,929,447	May 29, 1990	Yang			
	BF	4,933,184	June 12, 1990	Tsuk			
	BG	4,938,963	July 3, 1990	Parnell			
	BH	4,944,949	July 31, 1990	Story et al.			
	BI	4,968,716	Nov. 6, 1990	Markham			
	BJ	5,015,464	May 14, 1991	Strobridge			
	BK	5,070,085	Dec. 3, 1991	Markham			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BL	Hebert, Mary F. et al.; "Bioavailability of Cyclosporine with Concomitant Rifampin Administration is Markedly Less Than Predicted by Hepatic Enzyme Induction" (1992) <i>Clin. Pharmacol. Ther.</i> 52:453-457.
	BM	Kronbach, Thomas et al.; "Oxidation of Midazolam and Triazolam by Human Liver Cytochrome P450III A4" (1989) <i>Molec. Pharm.</i> 36:89-96.
	BN	Lalka et al.; "The Haptic First-Pass Metabolism of Problematic Drugs" (1993) <i>J. Clin. Pharmacol.</i> 33:657-669.
	BO	Lum et al.; "Clinical Trials of Modulation of Multidrug Resistance. Pharmacokinetic and Pharmacodynamic Considerations" (1993) <i>Cancer</i> 72:3502-3514.
	BP	Muranishi, Shozo; "Absorption Enhancers" (1990) <i>Crit. Rev. Ther. Drug Carrier Sys.</i> , 7:1-33.
	BQ	Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the 1990's" (1993) <i>J. Clin. Pharmacol.</i> 33:670-673.
	BR	Tam, Yun K.; "Individual Variation in First-Pass Metabolism" (1993) <i>Clin. Pharmacokinet.</i> 25:300-307.
	BS	Van Hoogdalem et al.; "Intestinal Drug Absorption Enhancement: An Overview" (1989) <i>Pharmacol. Ther.</i> 44:407-443.
	BT	Warren et al.; "Increased Accumulation of Drugs in Multidrug-Resistant Cell Induced by Liposomes" (1992) <i>Cancer Research</i> 52:3241-3245.
S.T.	BU	Watkins, Paul B.; "The Role of Cytochromes P-450 in Cyclosporine Metabolism" (1990) <i>J. Am. Acad. Dermatol.</i> 23:1301-1311.



Examiner

S.T.


Date Considered

5/29/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT (use several sheets if necessary)						Docket No. 112703-035	Serial No. 09/286,818
						Applicant Ream et al.	Group Art Unit 1761
Filing Date April 6, 1999							
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing Date If appropriate
S.T.	CA	5,124,156	June 23, 1992	Shibata et al.			
	CB	5,139,787	Aug. 18, 1992	Broderick et al.			
	CC	5,154,927	Oct. 13, 1992	Song et al.			
	CD	5,156,842	Oct. 20, 1992	Mulligan			
	CE	5,179,122	Jan. 12, 1993	Greene et al.			
	CF	5,182,099	Jan. 26, 1993	Jonsson et al.			
	CG	5,284,657	Feb. 8, 1994	Lu et al.			
	CH	5,294,449	Mar. 15, 1994	Greenberg			
	CI	5,340,566	Aug. 23, 1994	Curtis et al.			
	CJ	5,378,131	Jan. 3, 1995	Greenberg			
	CK	5,380,530	Jan. 10, 1995	Hill			
	CL	5,380,535	Jan. 10, 1995	Geyer et al.			
	CM	5,410,028	Apr. 25, 1995	Asami et al.			
	CN	5,445,834	Aug. 29, 1995	Burger et al.			
	CO	5,455,286	Oct. 3, 1995	Amidon et al.			
	CP	5,488,962	Feb. 6, 1996	Perfetti			
	CQ	5,496,541	Mar. 5, 1996	Cutler			
	CR	5,512,306	Apr. 30, 1996	Carlsson et al.			
	CS	5,534,272	July 9, 1996	Bernstein			
	CT	5,554,380	Sept. 10, 1996	Cuca et al.			
CU	5,571,528	Nov. 5, 1996	Lee et al.				
CV	5,585,110	Dec. 17, 1996	Kalili et al.				
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	CW	Wrighton et al.; "In Vitro Methods for Assessing Human Hepatic Drug Metabolism: Their Use in Drug Development" (1993) 25:453-484.					
	CX	Wu et al.; "Use of IV and Oral Drug Levels from Cyclosporene (CsA) with Concomitant Rifampin to Differentiate Gut Absorption and Metabolism" (1993) <i>Pharm. Res.</i> 10:abstract ppdm8185.					
S.T.	CY	Zamora et al.; "Physical-Chemical Properties Shared by Compounds that Modulate Multidrug Resistance in Human Loukemic Cells" (1988) <i>Molec. Pharmacol.</i> 33:454-462.					
Examiner	S.T.		Date Considered 5/29/01				
<b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT (use several sheets if necessary)						Docket No. 112703-035	Serial No. 09/286,818
						Applicant Ream et al.	
						Filing Date April 6, 1999	Group Art Unit 1761
U.S. PATENT DOCUMENTS							
Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing Date If appropriate
S.T	DA	5,593,685	Jan. 14, 1997	Bye et al.			
	DB	5,605,698	Feb. 25, 1997	Ueno			
	DC	5,618,517	Apr. 8, 1997	Miskewitz			
	DD	5,628,986	May 13, 1997	Sanker et al.			
	DE	5,629,035	May 13, 1997	Miskewitz			
	DF	5,645,853	July 8, 1997	Winston et al.			
	DG	5,665,386	Sept. 9, 1997	Benet et al.			
	DH	5,667,802	Dec. 16, 1997	Grimberg			
	DI	5,693,334	Dec. 2, 1997	Miskewitz			
	DJ	5,698,215	Dec. 16, 1997	Kalili et al.			
	DK	5,702,687	Dec. 30, 1997	Miskewitz			
	DL	5,716,928	Feb. 10, 1998	Benet et al.			
	DM	5,736,175	Apr. 7, 1998	Cea et al.			
	DN	5,744,164	Apr. 28, 1998	Chauffard et al.			
	DO	5,753,255	May 19, 1998	Chavkin et al.			
	DP	5,756,074	May 26, 1998	Ascione et al.			
	DQ	5,824,291	Oct. 20, 1998	Howard			
	DR	5,866,179	Feb. 2, 1999	Testa			
	DS	5,882,702	Mar. 16, 1999	Abdel-Malik et al.			
	DT	5,900,230	May 4, 1999	Cutler			
	DU	5,912,030	June 15, 1999	Huzinec et al.			
	DV	5,922,346	July 13, 1999	Hersh			
	DW	5,958,380	Sept. 28, 1999	Winston et al.			
S.T	DX	5,958,472	Sept. 28, 1999	Robinson et al.			
Examiner S.T			Date Considered 5/29/01				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							